Clinical Trials Logo

Hepatitis clinical trials

View clinical trials related to Hepatitis.

Filter by:

NCT ID: NCT00895882 Withdrawn - Clinical trials for Chronic Genotype 1 Hepatitis C Virus Infection

Study to Evaluate Different Regimens of Vaniprevir (MK7009) for the Treatment of Chronic Genotype 1 Hepatitis C Virus Infection in Treatment-naive Patients (MK-7009-019)(WITHDRAWN)

Start date: November 2010
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety, tolerability, and efficacy of vaniprevir when administered concomitantly with pegylated interferon (peg-IFN) and ribavirin (RBV) to treat treatment-naive genotype 1 hepatitis C virus (HCV)-infected patients.

NCT ID: NCT00876174 Withdrawn - Chronic Hepatitis C Clinical Trials

Effects of Genotypes on Interferon Signaling in Chronic Hepatitis C

Start date: April 15, 2009
Phase:
Study type: Observational

The objective of this pilot project is to investigate the prognostic criteria for sensitivity of Chronic Hepatitis C (CHC) Genotype 1, patients to IFNa treatment. Signal transduction in peripheral blood mononuclear cell (PBMC) of control groups will be compared with that of CHC patients. For this study, 20 patients with Hepatitis C virus (HCV) infection who are to undergo standard antiviral therapy and 10 healthy donors (significant others of the HCV subject) will be enrolled. Signal transduction will be studied in peripheral blood of CHC subjects before the treatment, after 1 and 3 months of treatment, and 4-6 months following the completion of treatment.

NCT ID: NCT00862706 Withdrawn - Clinical trials for Compensated Chronic Hepatitis B

Efficacy of Telbivudine in Blacks/African Americans and Hispanics/Latinos With Compensated Chronic Hepatitis B During 52 Weeks

Start date: April 2009
Phase: Phase 4
Study type: Interventional

The purpose of this study is to investigate the efficacy of telbivudine in Blacks/African Americans and Hispanics/Latinos with compensated chronic hepatitis B during 52 weeks of treatment

NCT ID: NCT00814606 Withdrawn - Hepatitis C Clinical Trials

A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C

Start date: February 2010
Phase: Phase 2
Study type: Interventional

This study seeks to evaluate the safety and efficacy of taking fluvastatin along with peginterferon alfa in previous partial responders with genotype 1 HCV.

NCT ID: NCT00800787 Withdrawn - Clinical trials for Hepatitis B, Chronic

Nabi-HB Administered Subcutaneously in Patients With Hepatitis B Virus Post Liver Transplantation

Nabi-HB-SC
Start date: April 2010
Phase: Phase 3
Study type: Interventional

A phase 3, multicenter, open label study to assess the safety and efficacy of Nabi-HB, administered subcutaneously in patients with Hepatitis B Virus Associated Liver Disease who underwent liver transplantation.

NCT ID: NCT00782301 Withdrawn - Hepatitis B Clinical Trials

Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients

Start date: March 2009
Phase: Phase 4
Study type: Interventional

Confirm the safety of maraviroc when used as a component of combination antiretroviral therapy in HIV and Hepatitis co-infected patients.

NCT ID: NCT00715715 Withdrawn - Chronic Hepatitis B Clinical Trials

Efficacy Study of Prednisone Priming to Treat Asian Chronic Hepatitis B Patients

Start date: April 2008
Phase: N/A
Study type: Interventional

Patients with chronic hepatitis B constantly produce the virus in the body. The disease of chronic hepatitis B is the body responding to the virus. Use of steroids can adjust this response. After taking steroids, viral production usually increases and liver function tests increase. After stopping steroids, viral production usually decreases. Many studies in the past have studied taking a low dose steroid before treating hepatitis B. Those studies have shown that low dose steroids help your body to clear the virus. The goal of this study is to improve the liver function by slowing viral growth.

NCT ID: NCT00710216 Withdrawn - Clinical trials for Hepatitis B, Chronic

Comparison of Telbivudine Versus Lamivudine on the Early Dynamics and Kinetics of Viral Suppression in Chronic Hepatitis B

EVD
Start date: n/a
Phase: Phase 4
Study type: Interventional

This study examines the effect of telbivudine compared to lamivudine on the early viral kinetics in patients with chronic hepatitis B. The virus Kinetics is measured by the viral load (HBV-DNA) reduction in the serum during the first 12 weeks of therapy.

NCT ID: NCT00704756 Withdrawn - Hepatitis C Clinical Trials

An Observational Study of Patients With Chronic Hepatitis C Undergoing Treatment With PegIntron and Rebetol in Clinical Practice in Belgium (Study P05494)(WITHDRAWN)

PEGIMPACT
Start date: January 2009
Phase: N/A
Study type: Observational

This is an observational study of patients undergoing treatment with PegIntron and Rebetol for chronic hepatitis C in clinical practice in Belgium. Treatment will not be administered as part of the study. Safety parameters will be assessed retrospectively. Efficacy parameters, such as relapse rates and sustained virologic response rates, will be assessed prospectively. The objective of the study is to examine any associations between safety, virologic, histologic, demographic parameters and patient outcome (relapse rates and sustained virologic response rates).

NCT ID: NCT00682591 Withdrawn - Clinical trials for Chronic Hepatitis C Infection

Evaluation of Neurocognitive Performance in Drug Substituted Patients Under Hepatitis C Therapy

Start date: July 2008
Phase: N/A
Study type: Observational

Prospective, longitudinal multi-center study performed in 15 participating substitution centers in Germany. Aims: - Primary objective: To compare the impact of the different substitution drugs (methadone, buprenorphine, and suboxone) on the neurocognitive, emotional, and quality-of-life-related tolerability in opioid dependent patients under HCV treatment. - Secondary objective: To investigate if IFN therapy impairs efficacy (with respect to e.g. retention rates, concomitant drug use and in particular neurocognitive function) and tolerability of agonist maintenance treatment with methadone, buprenorphine, or suboxone